Cargando…

Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China

In this study, we attenuated a Chinese QX-like nephropathogenic infectious bronchitis virus (IBV) strain, YX10, by passaging through fertilized chicken eggs. The 90th passage strain (YX10p90) was selected as the live-attenuated vaccine candidate strain. YX10p90 was found to be safe in 7-day-old spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Keyu, Xue, Yu, Wang, Jinglan, Chen, Weiguo, Chen, Feng, Bi, Yingzuo, Xie, Qingmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127481/
https://www.ncbi.nlm.nih.gov/pubmed/25636916
http://dx.doi.org/10.1016/j.vaccine.2015.01.036
_version_ 1783516369805901824
author Feng, Keyu
Xue, Yu
Wang, Jinglan
Chen, Weiguo
Chen, Feng
Bi, Yingzuo
Xie, Qingmei
author_facet Feng, Keyu
Xue, Yu
Wang, Jinglan
Chen, Weiguo
Chen, Feng
Bi, Yingzuo
Xie, Qingmei
author_sort Feng, Keyu
collection PubMed
description In this study, we attenuated a Chinese QX-like nephropathogenic infectious bronchitis virus (IBV) strain, YX10, by passaging through fertilized chicken eggs. The 90th passage strain (YX10p90) was selected as the live-attenuated vaccine candidate strain. YX10p90 was found to be safe in 7-day-old specific pathogen free chickens without induction of morbidity or mortality. YX10p90 provided nearly complete protection against QX-like (CH I genotype) strains and partial protection against other two major Chinese genotype strains. YX10p90 also showed no reversion to virulence after five back passages in chickens. An IBV polyvalent vaccine containing YX10p90 was developed and showed that it could provide better protection against major Chinese IBV virulent strains than commercial polyvalent vaccines. In addition, the complete genome sequence of YX10p90 was sequenced. Multiple-sequence alignments identified 38 nucleotide substitutions in the whole genome which resulted in 26 amino acid substitutions and a 110-bp deletion in the 3′ untranslated region. In conclusion, the attenuated YX10p90 strain exhibited a fine balance between attenuation and immunogenicity, and should be considered as a candidate vaccine to prevent infection of Chinese QX-like nephropathogenic IBV.
format Online
Article
Text
id pubmed-7127481
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71274812020-04-08 Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China Feng, Keyu Xue, Yu Wang, Jinglan Chen, Weiguo Chen, Feng Bi, Yingzuo Xie, Qingmei Vaccine Article In this study, we attenuated a Chinese QX-like nephropathogenic infectious bronchitis virus (IBV) strain, YX10, by passaging through fertilized chicken eggs. The 90th passage strain (YX10p90) was selected as the live-attenuated vaccine candidate strain. YX10p90 was found to be safe in 7-day-old specific pathogen free chickens without induction of morbidity or mortality. YX10p90 provided nearly complete protection against QX-like (CH I genotype) strains and partial protection against other two major Chinese genotype strains. YX10p90 also showed no reversion to virulence after five back passages in chickens. An IBV polyvalent vaccine containing YX10p90 was developed and showed that it could provide better protection against major Chinese IBV virulent strains than commercial polyvalent vaccines. In addition, the complete genome sequence of YX10p90 was sequenced. Multiple-sequence alignments identified 38 nucleotide substitutions in the whole genome which resulted in 26 amino acid substitutions and a 110-bp deletion in the 3′ untranslated region. In conclusion, the attenuated YX10p90 strain exhibited a fine balance between attenuation and immunogenicity, and should be considered as a candidate vaccine to prevent infection of Chinese QX-like nephropathogenic IBV. Elsevier Ltd. 2015-02-25 2015-01-27 /pmc/articles/PMC7127481/ /pubmed/25636916 http://dx.doi.org/10.1016/j.vaccine.2015.01.036 Text en Copyright © 2015 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Feng, Keyu
Xue, Yu
Wang, Jinglan
Chen, Weiguo
Chen, Feng
Bi, Yingzuo
Xie, Qingmei
Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China
title Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China
title_full Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China
title_fullStr Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China
title_full_unstemmed Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China
title_short Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China
title_sort development and efficacy of a novel live-attenuated qx-like nephropathogenic infectious bronchitis virus vaccine in china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127481/
https://www.ncbi.nlm.nih.gov/pubmed/25636916
http://dx.doi.org/10.1016/j.vaccine.2015.01.036
work_keys_str_mv AT fengkeyu developmentandefficacyofanovelliveattenuatedqxlikenephropathogenicinfectiousbronchitisvirusvaccineinchina
AT xueyu developmentandefficacyofanovelliveattenuatedqxlikenephropathogenicinfectiousbronchitisvirusvaccineinchina
AT wangjinglan developmentandefficacyofanovelliveattenuatedqxlikenephropathogenicinfectiousbronchitisvirusvaccineinchina
AT chenweiguo developmentandefficacyofanovelliveattenuatedqxlikenephropathogenicinfectiousbronchitisvirusvaccineinchina
AT chenfeng developmentandefficacyofanovelliveattenuatedqxlikenephropathogenicinfectiousbronchitisvirusvaccineinchina
AT biyingzuo developmentandefficacyofanovelliveattenuatedqxlikenephropathogenicinfectiousbronchitisvirusvaccineinchina
AT xieqingmei developmentandefficacyofanovelliveattenuatedqxlikenephropathogenicinfectiousbronchitisvirusvaccineinchina